Highlight

PAST & PRESENT

From Origination to Closing

Since its inception in 2010, SIMI has been producing productive discussions resulting in multiple successful partnerships and collaborations. As a brief synopsis of our track record, in 2018, SIMI originated and led the $667.6M deal between Roivant Science and iNtRON Biotechnology for a novel MRSA targeting antibacterial molecule and all of iNtRON’s remaining endolysin pipelines at right-of-first negotiation and pre-determined terms for licensing. In 2017, SIMI negotiated and consulted HanAll Biopharma’s exclusive license of their novel immunology product to Harbour BioMed and Roivant Science for $81M and over $500M respectively. In 2012, SIMI led the $139M deal between AstraZeneca and Legochem for their antibiotic program, which received the honor of being shortlisted for the 2013 SCRIP Award for Best Partnership Alliance.

  • $667.6M

    Licensing-Out Agreement

  • $502.5M

    Licensing-Out Agreement

  • $81M

    Licensing-Out Agreement

  • Undisclosed

    Spin-off / Joint Venture Agreement

  • Undisclosed

    Licensing-Out Agreement

  • $139M

    Collaboration & Option Licensing Agreement